A Plasma Metabolomic Signature for the Early Diagnosis of Sepsis: A Prospective Diagnostic Study
Early diagnosis of sepsis is limited by nonspecific clinical signs, slow and often negative blood cultures, and imperfect biomarkers. We evaluated whether plasma metabolomic profiling distinguishes sepsis from nonseptic acute illness better than procalcitonin (PCT), C-reactive protein (CRP) and lactate. Methods: In this prospective diagnostic study at a tertiary teaching hospital in India, 60 adults with sepsis (Sepsis-3) and 60 acutely ill nonseptic controls were enrolled consecutively from the emergency department and intensive care unit. Plasma was profiled by untargeted ultra-performance liquid chromatography–quadrupole time-of-flight mass spectrometry (UPLC–Q-TOF-MS). Analysis used orthogonal partial least-squares discriminant analysis (OPLS-DA), false-discovery-rate (FDR) corrected univariate tests, pathway enrichment, receiver operating characteristic (ROC) analysis, LASSO selection and logistic regression with bootstrap validation. Results: Groups were matched for age, sex, body mass index and comorbidities. Of 3,946 quality-controlled features, 312 differed significantly (FDR q < 0.05; |fold change| ≥ 1.5), and OPLS-DA separated the groups (R²Y = 0.86; Q² = 0.71; permutation P < 0.001). Sepsis showed raised kynurenine, N-formyl-methionine, N-lactoyl-phenylalanine, lactate and acylcarnitines, with lower tryptophan, arginine, citrulline and lysophosphatidylcholines. Tryptophan metabolism and arginine biosynthesis were the most enriched pathways. The kynurenine/tryptophan ratio (AUROC 0.89) outperformed PCT (0.82), CRP (0.76) and lactate (0.73). A five-metabolite panel achieved AUROC 0.93 (sensitivity 88.3%, specificity 86.7%). Adding the panel to conventional markers raised AUROC from 0.85 to 0.96 (DeLong P = 0.002; optimism-corrected 0.94; NRI 0.62). Conclusion: Early sepsis carries a distinct plasma metabolic signature. A five-metabolite panel discriminated sepsis from nonseptic acute illness better than PCT, CRP or lactate and improved a conventional-marker model. External validation with targeted assays is required.